NVIDIA and Novo Nordisk Partner to Accelerate AI-Driven Drug Discovery

Intelligent Finance APP learned that chipmaker NVIDIA (NVDA.US) announced a partnership with Novo Nordisk (NVO.US) on Wednesday to accelerate the Danish pharmaceutical giant's efforts in utilizing artificial intelligence (AI) for drug development.

This collaboration is expected to support the agreement reached between Novo Nordisk and the Danish AI Innovation Center, which owns and operates Denmark's flagship AI supercomputer, Gefion.

As part of the collaboration, the two companies will focus on developing customized artificial intelligence models for Novo Nordisk researchers to use in the early stages of clinical development, as well as running advanced simulations and physics-based artificial intelligence technologies.

Rory Kelleher, Senior Director of Business Development for Life Sciences at NVIDIA, said: "By collaborating with Novo Nordisk, we are advancing critical R&D applications using foundational tools that fully harness the potential of generative and agent-based AI to improve drug development."

NVIDIA announced the news at the GTC event held in Paris, France, where the company also unveiled several key European partners.